Nothing Special   »   [go: up one dir, main page]

EA201290552A1 - Способ производства фармацевтически активного вещества - Google Patents

Способ производства фармацевтически активного вещества

Info

Publication number
EA201290552A1
EA201290552A1 EA201290552A EA201290552A EA201290552A1 EA 201290552 A1 EA201290552 A1 EA 201290552A1 EA 201290552 A EA201290552 A EA 201290552A EA 201290552 A EA201290552 A EA 201290552A EA 201290552 A1 EA201290552 A1 EA 201290552A1
Authority
EA
Eurasian Patent Office
Prior art keywords
manufacture
active substance
pharmaceutical active
preparing
disclosed
Prior art date
Application number
EA201290552A
Other languages
English (en)
Other versions
EA021440B1 (ru
Inventor
Франс Теркельсен
Майкл Хэролд Рок
Свенн Треппендахль
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA201290552A1 publication Critical patent/EA201290552A1/ru
Publication of EA021440B1 publication Critical patent/EA021440B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Раскрываются способы получения фармацевтически активного агента и его фармацевтически приемлемых солей.
EA201290552A 2009-12-23 2010-12-20 Способ производства фармацевтически активного вещества EA021440B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23
PCT/DK2010/050348 WO2011076212A2 (en) 2009-12-23 2010-12-20 Processes for the manufacture of a pharmaceutically active agent

Publications (2)

Publication Number Publication Date
EA201290552A1 true EA201290552A1 (ru) 2012-12-28
EA021440B1 EA021440B1 (ru) 2015-06-30

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290552A EA021440B1 (ru) 2009-12-23 2010-12-20 Способ производства фармацевтически активного вещества

Country Status (37)

Country Link
US (3) US8461353B2 (ru)
EP (1) EP2516394B1 (ru)
JP (2) JP5864435B2 (ru)
KR (2) KR101873182B1 (ru)
CN (2) CN103694161B (ru)
AR (1) AR079580A1 (ru)
AU (1) AU2010335659B2 (ru)
BR (1) BR112012015749A2 (ru)
CA (1) CA2785440C (ru)
CL (1) CL2012001725A1 (ru)
CR (1) CR20120316A (ru)
CY (1) CY1118032T1 (ru)
DK (1) DK2516394T3 (ru)
DO (1) DOP2012000170A (ru)
EA (1) EA021440B1 (ru)
ES (1) ES2575666T3 (ru)
GE (1) GEP20146078B (ru)
HK (2) HK1174921A1 (ru)
HR (1) HRP20160518T1 (ru)
HU (1) HUE028806T2 (ru)
IL (2) IL220329A (ru)
MA (1) MA33945B1 (ru)
ME (1) ME02401B (ru)
MX (1) MX2012007078A (ru)
MY (1) MY159251A (ru)
NZ (2) NZ625798A (ru)
PL (1) PL2516394T3 (ru)
PT (1) PT2516394E (ru)
RS (1) RS54820B1 (ru)
SG (1) SG181910A1 (ru)
SI (1) SI2516394T1 (ru)
SM (1) SMT201600166B (ru)
TN (1) TN2012000279A1 (ru)
TW (1) TW201139370A (ru)
UA (1) UA111584C2 (ru)
WO (1) WO2011076212A2 (ru)
ZA (1) ZA201305936B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
TW201630881A (zh) 2014-12-12 2016-09-01 Ｈ 朗德貝克公司 用於生產艾達魯吡啶之方法
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN108271369A (zh) * 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
EP3440055B1 (en) * 2016-04-08 2020-03-11 H. Lundbeck A/S A process for the manufacture of idalopirdine via hydrogenation of an imine
EP3333154A1 (en) * 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist
CN113165992B (zh) * 2018-12-27 2024-08-06 豪夫迈·罗氏有限公司 制备外-n-(3-氮杂双环[3.2.1]辛烷-8-基)氨基甲酸叔丁酯的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
WO1995018090A1 (fr) 1993-12-28 1995-07-06 Rhone-Poulenc Chimie Procede d'hydrogenation catalytique de nitriles en amines en presence d'un catalyseur de type nickel de raney dope
CN1082389C (zh) 1993-12-28 2002-04-10 罗纳布朗克化学公司 用于将腈催化加氢为胺的催化剂及其制备方法和用途
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
WO1999022561A2 (en) 1997-10-31 1999-05-14 Koninklijke Philips Electronics N.V. A method and apparatus for audio representation of speech that has been encoded according to the lpc principle, through adding noise to constituent signals therein
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
US20090203577A1 (en) 2005-12-15 2009-08-13 Exelixis, Inc. Azepinoindole Derivatives As Pharmaceutical Agents
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
CN101531624A (zh) 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
SI2516394T1 (sl) 2016-07-29
CY1118032T1 (el) 2017-05-17
CA2785440C (en) 2018-05-01
CR20120316A (es) 2012-08-16
JP5864435B2 (ja) 2016-02-17
AU2010335659B2 (en) 2015-05-21
HK1196352A1 (en) 2014-12-12
TN2012000279A1 (en) 2013-12-12
US9382205B2 (en) 2016-07-05
NZ625798A (en) 2014-10-31
PL2516394T3 (pl) 2016-09-30
IL220329A (en) 2016-03-31
EA021440B1 (ru) 2015-06-30
IL231141A (en) 2016-03-31
US20130245281A1 (en) 2013-09-19
CN102656146A (zh) 2012-09-05
CA2785440A1 (en) 2011-06-30
CN103694161A (zh) 2014-04-02
TW201139370A (en) 2011-11-16
KR20170125417A (ko) 2017-11-14
DK2516394T3 (en) 2016-06-13
SG181910A1 (en) 2012-08-30
JP2016117734A (ja) 2016-06-30
WO2011076212A2 (en) 2011-06-30
HUE028806T2 (en) 2017-01-30
US20150080584A1 (en) 2015-03-19
NZ600639A (en) 2014-07-25
IL231141A0 (en) 2014-03-31
US8901318B2 (en) 2014-12-02
SMT201600166B (it) 2016-07-01
CN103694161B (zh) 2015-09-09
ZA201305936B (en) 2015-09-30
KR101796330B1 (ko) 2017-11-09
WO2011076212A3 (en) 2011-08-11
AU2010335659A1 (en) 2012-07-05
US8461353B2 (en) 2013-06-11
HRP20160518T1 (hr) 2016-06-03
MX2012007078A (es) 2012-07-20
MY159251A (en) 2016-12-30
IL220329A0 (en) 2012-08-30
JP6195605B2 (ja) 2017-09-13
EP2516394B1 (en) 2016-03-16
CL2012001725A1 (es) 2012-11-30
JP2013515683A (ja) 2013-05-09
UA111584C2 (uk) 2016-05-25
ME02401B (me) 2016-09-20
EP2516394A2 (en) 2012-10-31
KR101873182B1 (ko) 2018-06-29
DOP2012000170A (es) 2012-08-31
MA33945B1 (fr) 2013-01-02
ES2575666T3 (es) 2016-06-30
KR20120112480A (ko) 2012-10-11
PT2516394E (pt) 2016-06-07
RS54820B1 (sr) 2016-10-31
GEP20146078B (en) 2014-04-10
US20110152539A1 (en) 2011-06-23
HK1174921A1 (en) 2013-06-21
BR112012015749A2 (pt) 2015-09-15
CN102656146B (zh) 2014-12-17
AR079580A1 (es) 2012-02-01

Similar Documents

Publication Publication Date Title
EA201290552A1 (ru) Способ производства фармацевтически активного вещества
FR19C1040I2 (fr) Administration par voie respiratoire de principes actifs
CY1123208T1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
ECSP11011526A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
EA201391087A1 (ru) Оральные лекарственные формы препарата тазоцитиниба с модифицированным высвобождением
CL2011002222A1 (es) Metodo para preparar una proteina biologica condicionalmente activa; metodo para preparar un modificador condicionalmente activo de respuesta biologica.
MY163083A (en) Solid forms of a pharmaceutically active substance
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
EA201190161A1 (ru) Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения
BRPI0913730A2 (pt) série de derivados de aminobenzoíla, sais farmaceuticamente aceitaveis, composições farmacêuticas, compostos, método para preparar os ditos compostos e usos
EA201391524A1 (ru) Производные гликозида и их применение
UY33348A (es) Compuestos de furopiridina y usos de los mismos
MX340098B (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.
EA201291097A1 (ru) Финголимод в форме гранулированного расплава
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
TN2014000060A1 (en) Benzothiazolone compound

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU